Matthew Keller
Stock Analyst at H.C. Wainwright
(0.05)
# 4,366
Out of 4,386 analysts
84
Total ratings
15.4%
Success rate
-26.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GALT Galectin Therapeutics | Reiterated: Buy | $11 | $2.40 | +358.33% | 9 | May 28, 2026 | |
| SXTP 60 Degrees Pharmaceuticals | Downgraded: Hold | n/a | $1.43 | - | 5 | May 20, 2026 | |
| GRI GRI Bio | Reiterated: Buy | $10 | $2.17 | +360.83% | 9 | May 14, 2026 | |
| KYNB Kyntra Bio | Reiterated: Buy | $43 | $6.72 | +540.28% | 13 | May 12, 2026 | |
| IFRX InflaRx | Rated: Buy | $6 → $8 | $1.71 | +367.84% | 10 | May 12, 2026 | |
| ACXP Acurx Pharmaceuticals | Reiterated: Buy | $31 | $1.62 | +1,813.58% | 10 | May 12, 2026 | |
| PHIO Phio Pharmaceuticals | Reiterated: Buy | $14 | $1.09 | +1,184.40% | 9 | May 8, 2026 | |
| GYRE Gyre Therapeutics | Reiterated: Buy | $18 | $6.05 | +197.52% | 10 | May 7, 2026 | |
| ITRMF Iterum Therapeutics plc | Downgraded: Hold | n/a | $0.04782 | - | 5 | Mar 30, 2026 | |
| SNSE Sensei Biotherapeutics | Downgraded: Hold | n/a | $13.00 | - | 4 | Oct 30, 2025 |
Galectin Therapeutics
May 28, 2026
Reiterated: Buy
Price Target: $11
Current: $2.40
Upside: +358.33%
60 Degrees Pharmaceuticals
May 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.43
Upside: -
GRI Bio
May 14, 2026
Reiterated: Buy
Price Target: $10
Current: $2.17
Upside: +360.83%
Kyntra Bio
May 12, 2026
Reiterated: Buy
Price Target: $43
Current: $6.72
Upside: +540.28%
InflaRx
May 12, 2026
Rated: Buy
Price Target: $6 → $8
Current: $1.71
Upside: +367.84%
Acurx Pharmaceuticals
May 12, 2026
Reiterated: Buy
Price Target: $31
Current: $1.62
Upside: +1,813.58%
Phio Pharmaceuticals
May 8, 2026
Reiterated: Buy
Price Target: $14
Current: $1.09
Upside: +1,184.40%
Gyre Therapeutics
May 7, 2026
Reiterated: Buy
Price Target: $18
Current: $6.05
Upside: +197.52%
Iterum Therapeutics plc
Mar 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.04782
Upside: -
Sensei Biotherapeutics
Oct 30, 2025
Downgraded: Hold
Price Target: n/a
Current: $13.00
Upside: -